We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-1.16%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.86B
AUM Growth
+$4.04B
Cap. Flow
+$4.05B
Cap. Flow %
69.18%
Top 10 Hldgs %
42.44%
Holding
220
New
83
Increased
86
Reduced
22
Closed
19

Top Buys

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$541M
2
INCY icon
Incyte
INCY
+$293M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$290M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$228M
5
SAGE
Sage Therapeutics
SAGE
+$223M

Top Sells

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$28.3M
2
COR icon
Cencora
COR
+$19.9M
3
PRAH
PRA Health Sciences, Inc.
PRAH
+$16.5M
4
WBA
Walgreens Boots Alliance
WBA
+$14.7M
5
ILMN icon
Illumina
ILMN
+$9.58M

Sector Composition

Rank Sector Weight
1 Healthcare 94.72%
2 Technology 0.56%
3 Industrials 0.42%
4 Financials 0.06%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QTTB icon
51
Q32 Bio
QTTB
$346M
$27.4M 0.47%
+77,896
New +$30.6M
BAX icon
52
Baxter International
BAX
$11.7B
$25.7M 0.44%
314,237
+21,063
+7% +$1.64M
HCA icon
53
HCA Healthcare
HCA
$82.3B
$25.2M 0.43%
186,745
+126,348
+209% +$16M
DXCM icon
54
DexCom
DXCM
$29.6B
$24.7M 0.42%
660,544
+135,960
+26% +$4.27M
HRC
55
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$24.4M 0.42%
233,198
+30,110
+15% +$3.05M
AMED
56
DELISTED
Amedisys
AMED
$21.2M 0.36%
174,310
+140,654
+418% +$16.7M
GTHX
57
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$20.6M 0.35%
+671,925
New +$14.1M
LIVN icon
58
LivaNova
LIVN
$4.43B
$19.1M 0.33%
265,666
+98,710
+59% +$7.22M
EVH icon
59
Evolent Health
EVH
$654M
$18.7M 0.32%
2,349,000
+940,763
+67% +$11.1M
CDNA icon
60
CareDx
CDNA
$2.05B
$17.7M 0.3%
492,008
+60,440
+14% +$1.93M
TMO icon
61
Thermo Fisher Scientific
TMO
$198B
$16.7M 0.29%
57,024
+18,166
+47% +$5M
FIT
62
DELISTED
Fitbit, Inc. Class A common stock
FIT
$16.3M 0.28%
3,696,530
+427,596
+13% +$2.15M
QDEL icon
63
QuidelOrtho
QDEL
$1.19B
$15.9M 0.27%
268,470
+44,890
+20% +$2.69M
INSM icon
64
Insmed
INSM
$23.5B
$15.9M 0.27%
620,459
-38,975
-6% -$1.09M
AVDR
65
DELISTED
Avedro, Inc Common Stock
AVDR
$15.8M 0.27%
804,379
+54,379
+7% +$872K
SUPN icon
66
Supernus Pharmaceuticals
SUPN
$2.79B
$15.5M 0.26%
467,000
+176,000
+60% +$6.03M
GNMK
67
DELISTED
GenMark Diagnostics, Inc
GNMK
$15.3M 0.26%
2,353,067
– –
CHNG
68
DELISTED
Change Healthcare Inc. Common Stock
CHNG
$14.6M 0.25%
+1,000,000
New +$14.8M
OMCL icon
69
Omnicell
OMCL
$2.09B
$14.3M 0.24%
166,715
+22,876
+16% +$1.86M
WMGI
70
DELISTED
Wright Medical Group Inc
WMGI
$14.3M 0.24%
478,495
-95,100
-17% -$2.9M
IRTC icon
71
iRhythm Holdings
IRTC
$3.64B
$14.1M 0.24%
178,848
+61,087
+52% +$4.45M
QTRX icon
72
Quanterix
QTRX
$182M
$13.4M 0.23%
397,569
+48,210
+14% +$1.25M
HCM icon
73
HUTCHMED
HCM
$1.86B
$13.2M 0.22%
598,310
– –
HMSY
74
DELISTED
HMS Holdings Corp.
HMSY
$12.9M 0.22%
398,442
+107,465
+37% +$3.29M
TFX icon
75
Teleflex
TFX
$5.96B
$12.2M 0.21%
36,766
+17,018
+86% +$5.14M
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2019 Portfolio in Review

As of Q2 2019, Bellevue Group held 220 positions worth $5.86B, up 222% from $1.82B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Bellevue Group deployed $4.05B of net new capital in Q2 2019, opening 83 new positions and adding to 86 existing holdings. Its largest new stake was Agios Pharmaceuticals: 3,128,134 shares worth $156M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 91% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Wellcare Health Plans, Inc., an estimated $28.3M trimmed.

  • Bellevue Group's largest Q2 2019 buy was Agios Pharmaceuticals: 3,128,134 shares worth $156M.
  • Bellevue Group added most to Ionis Pharmaceuticals in Q2 2019, an estimated $541M increase.
  • Bellevue Group's biggest Q2 2019 reduction was Wellcare Health Plans, Inc., cutting an estimated $28.3M.
  • Bellevue Group fully exited Cencora in Q2 2019, selling an estimated $19.9M.
  • Bellevue Group's ten largest holdings make up 42% of its $5.86B portfolio in Q2 2019.
  • Bellevue Group opened 83 new positions and closed 19 in Q2 2019.
  • Bellevue Group's portfolio value rose 222% quarter-over-quarter to $5.86B.

Based on Bellevue Group's 13F filing for Q2 2019, filed 14 Aug 2019.